C B Window Center is a research and development company based in Whittier, CA, dedicated to pioneering a novel medicine for fibrosis, aiming to prevent, heal, and slow organ scarring caused by fibrotic diseases.
Their highly selective, peripheral-acting 5 HT2B receptor antagonist, AM1476, has been granted Orphan Drug Designation in the US and EU for the treatment of Systemic Sclerosis, offering a unique dual-action potential to address both skin and lung manifestations of the disease. Supported by Phase I and preclinical proof-of-concept studies, AM1476 is Phase II ready.
Generated from the website